Evidence map›Paper›PMID 33425430›Full record

ReviewImmune network2020

Crosstalk between the Producers and Immune Targets of IL-9.

Van Anh Do-Thi, Jie-Oh Lee, Hayyoung Lee, Young Sang Kim

Open access · diamondAbstract readReview
In one paragraph

Review in Immune network, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Group 2 innate lymphoid cells derived IL-9 reduces macrophage apoptosis and attenuates acute lung injury in sepsis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  5. Th9 cells provide protective TB immunity.Frontiers in immunology · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Th2 cell clonal expansion at diagnosis in human type 1 diabetes.Clinical immunology (Orlando, Fla.) · 2023
    Article
  15. The World according to IL-9.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Van Anh Do-ThiDepartment of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea.ORCID https://orcid.org/0000-0003-4670-6386
Jie-Oh LeeDepartment of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea.ORCID https://orcid.org/0000-0001-6519-6049
Hayyoung LeeInstitute of Biotechnology, Chungnam National University, Daejeon 34134, Korea.ORCID https://orcid.org/0000-0002-8163-2880
Young Sang KimDepartment of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon 34134, Korea.ORCID https://orcid.org/0000-0002-2360-2595
Chungnam National University · KRPohang University of Science and Technology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IL-9 has been reported to play dual roles in the pathogenesis of autoimmune disorders and cancers. The collaboration of IL-9 with microenvironmental factors including the broader cytokine milieu and other cellular components may provide important keys to explain its conflicting effects in chronic conditions. In this review, we summarize recent findings on the cellular sources of, and immunological responders to IL-9, in order to interpret the role of IL-9 in the regulation of immune responses. This knowledge will provide new perspectives to improve clinical benefits and limit adverse effects of IL-9 when treating pathologic conditions.

Indexed as

AllergyAutoimmune diseasesCancer, Adaptive immunityInnate immunityInterleukin-9

Identifiers

PMID33425430
PMCPMC7779872
OpenAlexW3108056336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.